Drug General Information (ID: DDIE5KV6L1)
  Drug Name Dasatinib Drug Info Antithrombin III human Drug Info
  Drug Type Small molecule Protein/peptide
  Therapeutic Class Antineoplastics Recombinant Antithrombin

 Mechanism of Dasatinib-Antithrombin III human Interaction (Severity Level: Major)
     Increased risk of bleeding Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Dasatinib Antithrombin III human
      Mechanism Risk of bleeding
Antiplatelet effects 
Risk of bleeding
Anticoagulant 
      Key Mechanism Factor 1
Factor Name Bleeding
Factor Description Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
      Mechanism Description
  • Increased risk of bleeding by the combination of Dasatinib and Antithrombin III human 

Recommended Action
      Management Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with dasatinib. Close clinical and laboratory observation for bleeding complications is recommended during therapy. A complete blood count (CBC) with differential and platelet count should be obtained prior to and at least weekly for the first 2 months, then monthly thereafter or as clinically indicated. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.

References
1 Cerner Multum, Inc. "Australian Product Information.".
2 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.